1
|
Weinberg GL, Salamon P, Lamar JM. The Telluride YAP/TAZ and TEAD Workshop: A Small Meeting with a Big Impact. Cancers (Basel) 2023; 15:4717. [PMID: 37835411 PMCID: PMC10571809 DOI: 10.3390/cancers15194717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 09/18/2023] [Indexed: 10/15/2023] Open
Abstract
Funding the research needed to advance our understanding of rare cancers is very challenging [...].
Collapse
Affiliation(s)
- Guy L. Weinberg
- Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL 60612, USA;
| | - Peter Salamon
- Department of Mathematics and Statistics, San Diego State University, San Diego, CA 92182, USA;
| | - John M. Lamar
- Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY 12208, USA
| |
Collapse
|
2
|
Cortés-Sánchez JL, Callant J, Krüger M, Sahana J, Kraus A, Baselet B, Infanger M, Baatout S, Grimm D. Cancer Studies under Space Conditions: Finding Answers Abroad. Biomedicines 2021; 10:biomedicines10010025. [PMID: 35052703 PMCID: PMC8773191 DOI: 10.3390/biomedicines10010025] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 12/17/2021] [Accepted: 12/20/2021] [Indexed: 12/12/2022] Open
Abstract
In this review article, we discuss the current state of knowledge in cancer research under real and simulated microgravity conditions and point out further research directions in this field. Outer space is an extremely hostile environment for human life, with radiation, microgravity, and vacuum posing significant hazards. Although the risk for cancer in astronauts is not clear, microgravity plays a thought-provoking role in the carcinogenesis of normal and cancer cells, causing such effects as multicellular spheroid formation, cytoskeleton rearrangement, alteration of gene expression and protein synthesis, and apoptosis. Furthermore, deleterious effects of radiation on cells seem to be accentuated under microgravity. Ground-based facilities have been used to study microgravity effects in addition to laborious experiments during parabolic flights or on space stations. Some potential 'gravisensors' have already been detected, and further identification of these mechanisms of mechanosensitivity could open up ways for therapeutic influence on cancer growth and apoptosis. These novel findings may help to find new effective cancer treatments and to provide health protection for humans on future long-term spaceflights and exploration of outer space.
Collapse
Affiliation(s)
- José Luis Cortés-Sánchez
- Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany; (J.L.C.-S.); (M.K.); (A.K.); (M.I.)
| | - Jonas Callant
- Radiobiology Unit, Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK CEN), 2400 Mol, Belgium; (J.C.); (B.B.); (S.B.)
| | - Marcus Krüger
- Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany; (J.L.C.-S.); (M.K.); (A.K.); (M.I.)
- Research Group ‘Magdeburger Arbeitsgemeinschaft für Forschung unter Raumfahrt-und Schwerelosigkeitsbedingungen’ (MARS), Otto von Guericke University, 39106 Magdeburg, Germany
| | - Jayashree Sahana
- Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark;
| | - Armin Kraus
- Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany; (J.L.C.-S.); (M.K.); (A.K.); (M.I.)
- Research Group ‘Magdeburger Arbeitsgemeinschaft für Forschung unter Raumfahrt-und Schwerelosigkeitsbedingungen’ (MARS), Otto von Guericke University, 39106 Magdeburg, Germany
| | - Bjorn Baselet
- Radiobiology Unit, Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK CEN), 2400 Mol, Belgium; (J.C.); (B.B.); (S.B.)
| | - Manfred Infanger
- Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany; (J.L.C.-S.); (M.K.); (A.K.); (M.I.)
- Research Group ‘Magdeburger Arbeitsgemeinschaft für Forschung unter Raumfahrt-und Schwerelosigkeitsbedingungen’ (MARS), Otto von Guericke University, 39106 Magdeburg, Germany
| | - Sarah Baatout
- Radiobiology Unit, Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK CEN), 2400 Mol, Belgium; (J.C.); (B.B.); (S.B.)
- Department Molecular Biotechnology, Ghent University, 9000 Ghent, Belgium
| | - Daniela Grimm
- Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany; (J.L.C.-S.); (M.K.); (A.K.); (M.I.)
- Research Group ‘Magdeburger Arbeitsgemeinschaft für Forschung unter Raumfahrt-und Schwerelosigkeitsbedingungen’ (MARS), Otto von Guericke University, 39106 Magdeburg, Germany
- Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark;
- Correspondence: ; Tel.: +45-21379702
| |
Collapse
|
3
|
Matsuda T, Miyata Y, Nakamura Y, Otsubo A, Mukae Y, Harada J, Mitsunari K, Matsuo T, Ohba K, Furusato B, Sakai H. Pathological significance and prognostic role of LATS2 in prostate cancer. Prostate 2021; 81:1252-1260. [PMID: 34492128 PMCID: PMC9290072 DOI: 10.1002/pros.24226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/27/2021] [Accepted: 04/30/2021] [Indexed: 11/11/2022]
Abstract
BACKGROUND Large tumor suppressor 2 (LATS2) is an important regulator of the Hippo pathway and it plays crucial roles in cell survival and behaviors. Herein, we evaluated the pathological roles of LATS2 in prostate cancer (PC), for which very little information is available. METHODS Cell proliferation, migration, and invasion in response to the siRNA-mediated knockdown (KD) LATS2 expression were evaluated in two PC cell lines (LNCaP and PC3). The expression of LATS2 in specimens from 204 PC patients was investigated immunohistochemically, and the relationships between its expression and clinicopathological features, proliferation index (PI; measured using an anti-KI-67 antibody), and biochemical recurrence (BCR) were investigated. RESULTS KD of LATS2 increased the growth, migration, and invasion in LNCaP cells and only increased migration in PC3 cells. The expression of LATS2 was negatively associated with the grade group, T, N, M stage, and PI. In addition, the expression of LATS2 was a useful predictor of the histological effects of neoadjuvant hormonal therapy and BCR-free survival periods. A multivariate analysis model including clinicopathological features showed that negative expression of LATS2 had a significantly higher risk of BCR (odds ratio = 2.95, P < 0.001). CONCLUSIONS LATS2 acts as a tumor suppressor in PC. LATS2 expression is a useful predictor for BCR. LATS2-related activities are possibly dependent on the androgen-dependency of PC cells. Therefore, we suggest that LATS2 could be a potential therapeutic target and a useful predictor for outcome in patients with PC.
Collapse
Affiliation(s)
- Tsuyoshi Matsuda
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Yasuyoshi Miyata
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Yuichiro Nakamura
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Asato Otsubo
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Yuta Mukae
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Junki Harada
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Kensuke Mitsunari
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Tomohiro Matsuo
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Kojiro Ohba
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| | - Bungo Furusato
- Department of pathologyNagasaki University Graduate School of Biomedical ScienecesNagasakiJapan
| | - Hideki Sakai
- Department of UrologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
| |
Collapse
|
4
|
Zafar E, Maqbool MF, Iqbal A, Maryam A, Shakir HA, Irfan M, Khan M, Li Y, Ma T. A comprehensive review on anticancer mechanism of bazedoxifene. Biotechnol Appl Biochem 2021; 69:767-782. [PMID: 33759222 DOI: 10.1002/bab.2150] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 03/08/2021] [Indexed: 12/24/2022]
Abstract
Cancer is counted as a second leading cause of death among nontransmissible diseases. Identification of novel anticancer drugs is therefore necessary for the effective treatment of cancer. Conventional drug discovery is time consuming and expensive process. Unlike conventional drug discovery, drug repositioning offers a novel strategy for urgent drug discovery since it is a cost-effective and faster process. Bazedoxifene (BZA) is a synthetic selective estrogen receptor modulator, approved by the United States Food and Drug Administration for the treatment of osteoporosis in postmenopausal women. BZA is now being studied for its anticancer activity in various cancers including breast cancer, liver cancer, pancreatic cancer, colon cancer, head and neck cancer, medulloblastoma, brain cancer, and gastrointestinal cancer. Studies have reported that BZA is effective in reducing cancer progression through multiple mechanisms. BZA could effectively inhibit STAT3, PI3K/AKT, and MAPK signaling pathways and induce apoptosis. In addition to its anticancer activity as monotherapy, BZA has been shown to enhance the chemotherapeutic efficacy of clinical drugs such as paclitaxel, cisplatin, palbociclib, and oxaliplatin in multiple neoplasms. This review mainly focused on the anticancer activity, cellular targets, and anticancer mechanism of BZA, which may help the further design and conduct of research and repositioning it for oncological clinic trials.
Collapse
Affiliation(s)
- Erum Zafar
- Department of Zoology, University of the Punjab, Quaid-e-Azam Campus, Lahore, Pakistan
| | | | - Asia Iqbal
- Department of Wild Life and Ecology, University of Veternary and Animal Sciences, Ravi Campus, Patoki, Pakistan
| | - Amara Maryam
- Department of Zoology, University of the Punjab, Quaid-e-Azam Campus, Lahore, Pakistan
| | - Hafiz Abdullah Shakir
- Department of Zoology, University of the Punjab, Quaid-e-Azam Campus, Lahore, Pakistan
| | - Muhammad Irfan
- Department of Biotechnology, University of Sargodha, Sargodha, Pakistan
| | - Muhammad Khan
- Department of Zoology, University of the Punjab, Quaid-e-Azam Campus, Lahore, Pakistan
| | - Yongming Li
- School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China
| | - Tonghui Ma
- School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China
| |
Collapse
|
5
|
Rips J, Mor-Shaked H, Erdin S, Yanovsky-Dagan S, Eventov-Friedman S, Harel T. De novo variant in AMOTL1 in infant with cleft lip and palate, imperforate anus and dysmorphic features. Am J Med Genet A 2020; 185:190-195. [PMID: 33026150 DOI: 10.1002/ajmg.a.61901] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 08/06/2020] [Accepted: 09/05/2020] [Indexed: 12/19/2022]
Abstract
AMOTL1 belongs to the Motin family of proteins that are involved in organogenesis and tumorigenesis through regulation of cellular migration, tube formation, and angiogenesis. While involvement of all AMOTs in development or suppression of cancers is relatively well described, little is known about the congenital phenotype of pathogenic variants in these genes in humans. Recently, a heterozygous variant in AMOTL1 was published in association with orofacial clefts and cardiac abnormalities in an affected father and his daughter. However, studies in mice did not recapitulate the human phenotype and the case was summarized as inconclusive. We present a female infant with cleft lip and palate, imperforate anus and dysmorphic features, in whom trio exome sequencing revealed a de novo variant in AMOTL1 affecting a highly conserved amino acid (c.479C>T; p.[Pro160Leu]). Bioinformatic predictions and in silico modeling supported pathogenicity. This case reinforces the conjecture regarding the disruptive effect of pathogenic variants in AMOTL1 on organ formation in humans. Studies of additional families will reveal the full phenotypic spectrum associated with this multiple malformation syndrome.
Collapse
Affiliation(s)
- Jonathan Rips
- Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Hagar Mor-Shaked
- Department of Genetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Serkan Erdin
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Shira Yanovsky-Dagan
- Department of Genetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | | | - Tamar Harel
- Department of Genetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| |
Collapse
|
6
|
Shimoda M, Moroishi T. The Emerging Link between the Hippo Pathway and Non-coding RNA. Biol Pharm Bull 2020; 43:1-10. [DOI: 10.1248/bpb.b19-00795] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Mayuko Shimoda
- Department of Cell Signaling and Metabolic Medicine, Faculty of Life Sciences, Kumamoto University
| | - Toshiro Moroishi
- Department of Cell Signaling and Metabolic Medicine, Faculty of Life Sciences, Kumamoto University
- Center for Metabolic Regulation of Health Aging, Faculty of Life Sciences, Kumamoto University
- Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency (JST)
| |
Collapse
|
7
|
Fu W, Zhao P, Li H, Fu H, Liu X, Liu Y, Wu J, Fu W. Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo/YAP pathway. J Cancer 2020; 11:657-667. [PMID: 31942189 PMCID: PMC6959043 DOI: 10.7150/jca.38350] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 11/13/2019] [Indexed: 01/10/2023] Open
Abstract
Glioblastoma multiform (GBM) is an aggressive type of brain tumor originated from astrocytes. Owing to the limited therapeutic options, intensive efforts are still being made to find novel treatments for GBM. In this study, we first identified that bazedoxifene bore the ability to reduce cell survival and cell invasion of glioblastoma cells. Furthermore, our results also revealed that bazedoxifene combining with paclitaxel had better efficacy to suppress glioblastoma progression by promoting apoptosis and reducing EMT. Combination of bazedoxifene and paclitaxel also accelerated YAP phosphorylation and inactivation. Importantly, preclinical animal model also verified our in vitro findings. Together, our data not only define the underlying mechanism responsible for action of bazedoxifene on glioblastoma cells but also build strong rational to develop bazedoxifene for the treatment of GBM patients.
Collapse
Affiliation(s)
- Weiwei Fu
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P. R. China
| | - Peng Zhao
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P. R. China
| | - Hong Li
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P. R. China
| | - Haiyang Fu
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P. R. China
| | - Xuejun Liu
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P. R. China
| | - Yingchao Liu
- Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250006, P. R. China
| | - Jie Wu
- Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250006, P. R. China
| | - Weiwei Fu
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P. R. China
| |
Collapse
|
8
|
Nishio M, Miyachi Y, Otani J, Tane S, Omori H, Ueda F, Togashi H, Sasaki T, Mak TW, Nakao K, Fujita Y, Nishina H, Maehama T, Suzuki A. Hippo pathway controls cell adhesion and context‐dependent cell competition to influence skin engraftment efficiency. FASEB J 2019; 33:5548-5560. [DOI: 10.1096/fj.201802005r] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Miki Nishio
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
- Division of Cancer GeneticsDepartment of Molecular GeneticsMedical Institute of BioregulationKyushu University Fukuoka Japan
| | - Yousuke Miyachi
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
- Division of Cancer GeneticsDepartment of Molecular GeneticsMedical Institute of BioregulationKyushu University Fukuoka Japan
| | - Junji Otani
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
| | - Shoji Tane
- Division of Cancer GeneticsDepartment of Molecular GeneticsMedical Institute of BioregulationKyushu University Fukuoka Japan
| | - Hirofumi Omori
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
| | - Fumihito Ueda
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
| | - Hideru Togashi
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
| | - Takehiko Sasaki
- Department of Lipid BiologyTokyo Medical and Dental University Tokyo Japan
| | - Tak Wah Mak
- The Campbell Family Institute for Breast Cancer ResearchPrincess Margaret Cancer Centre Toronto Ontario Canada
- Department of Medical BiophysicsUniversity of TorontoUniversity Health Network Toronto Ontario Canada
| | - Kazuwa Nakao
- Medical Innovation CenterGraduate School of MedicineKyoto University Kyoto Japan
| | - Yasuyuki Fujita
- Division of Molecular OncologyInstitute for Genetic MedicineGraduate School of Chemical Sciences and EngineeringHokkaido University Sapporo Japan
| | - Hiroshi Nishina
- Department of Developmental and Regenerative BiologyMedical Research InstituteTokyo Medical and Dental University Tokyo Japan
| | - Tomohiko Maehama
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
| | - Akira Suzuki
- Division of Molecular and Cellular BiologyDepartment of Biochemistry and Molecular BiologyKobe University Graduate School of MedicineKobe University Kobe Japan
- Division of Cancer GeneticsDepartment of Molecular GeneticsMedical Institute of BioregulationKyushu University Fukuoka Japan
| |
Collapse
|
9
|
Hippo Pathway in Cancer, towards the Realization of Hippo-Targeted Therapy. Cancers (Basel) 2018; 10:cancers10100383. [PMID: 30322038 PMCID: PMC6210146 DOI: 10.3390/cancers10100383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 10/10/2018] [Indexed: 12/03/2022] Open
|